CAS: 31329-57-4; 2-(Diethylamino)Ethyl 3-(Naphthalen-1-yl)-2-((Tetrahydrofuran-2-yl)Methyl)Propanoate

该化合物是一种化学化合物,主要用作血管病,经常用于治疗边缘血管疾病,其特点是能够通过分层血管改善血液流动,这可以帮助缓解与间歇性阴道结扎等条件有关的症状;化合物工作是抑制板块聚集,提高组织氧气利用率;甲夫提德罗弗林通常以口服形式进行,以其相对较低的副作用特征而闻名于其他血管病;其化学结构包括一个柔性球菌组,它有助于其药性特性;该物质一般被很好地调用,但像任何药物一样,它可能与其他药物有反作用和潜在相互作用;与任何治疗剂一样,病人必须咨询保健专业人员,以获得个性化建议并确保安全使用.

结构式图片

欧盟法规

REACH注册ECHA物质REACH预注册

上下游产品

CAS号98-01-1 糠醛 | CAS号17448-96-3 2-(呋喃-2-基亚甲基)丙二酸二乙酯 | CAS号1192-30-9 2-溴甲基四氢呋喃 | CAS号97-99-4 四氢糠醇 | CAS号85068-37-7 Diethyl (1-naph... | CAS号37136-39-3 四氢呋喃丙二酸二乙酯 | CAS号86-52-2 1-氯甲基萘 | CAS号113527-39-2 1-(tetrahydro-2... | CAS号77-78-1 硫酸二甲酯 | CAS号100-37-8 二乙氨基乙醇 | CAS号3200-06-4 萘呋胺酯 草酸盐

合成工艺路线路线简述

    📜(S)-(Tetrahydrofuran-2-yl)Methyl 4-Methylbenzenesulfonate置于氢氧化钾,Sodium Methylate,碳酸二甲酯体系中,化学反应 56.5H,反应生成(As,2R)-四氢-A-(1-萘甲基)-2-呋喃丙酸 2-(二乙基氨基)乙酯
    参考文献:萘呋喃基异构体的最佳异构体(= 2-[(萘-1-基)甲基]-3-(四氢呋喃-2-基)丙酸酯和2-(二乙基氨基)乙酸酯)
    标题:萘呋喃基异构体的最佳异构体(= 2-[(萘-1-基)甲基]-3-(四氢呋喃-2-基)丙酸酯和2-(二乙基氨基)乙酸酯)
    摘要:萘呋喃基糠酸酯的光学异构体(= 2-[(diethylamino)ethyl 2-[((萘-1-基)甲基]]-3-(四氢呋喃-2-基)丙酸酯)
    Doi:10.1002/hlca.19910740818

    海关参考信息

    专利信息


    专利号:WO-2020025646-A1
    优先权日:2018-07-30
    标题:An omega-transaminase enzyme
    发明人:MAGUIRE ANITA; GAVIN DECLAN; O'GARA FERGAL; REEN JERRY
    权利人:UNIV COLLEGE CORK NATIONAL UNIV OF IRELAND CORK
    摘要:An isolated w-transaminase enzyme comprising an amino acid sequence of SEQUENCE ID NO: 1, or encoded by a nucleic acid sequence of SEQUENCE ID NO: 2, is provided which is derived from marine sponge Pseudovibrio sp.. Also provided are functional variants of the w-transaminase enzyme that are isolated, have at least 80% sequence identity with SEQUENCE ID NO: 1, and are capable of enantioselectively resolving a racemic amine by transformation to a ketone by oxidative deamination, or enantioselectively resolving a racemic ketone by transformation to an amine by reductive amination, in which the amine and ketone typically contain a stereocentre removed from the reacting site. An example of a functional variant is SEQUENCE ID NO:3. In one embodiment, the functional variant is capable of enantioselectively transforming a (4S) -tetralone intermediate in the synthesis of sertraline, in which the functional variant displays remote stereospecificity for the tetralone intermediate.

    专利号:US-2023271983-A1
    优先权日:2020-07-29
    标题 :Functionalized isonitriles and products, preparation and uses thereof
    发明人:SOTELO PÉREZ EDDY; AZUAJE GUERRERO JHONNY ALBERTO; MAJELLARO MARIA
    权利人:UNIV SANTIAGO COMPOSTELA
    摘要:The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.

    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2012 Dec 12;12:CD001368. doi: 10.1002/14651858.CD001368.pub4. Review. doi: 10.1002/14651858.CD002070.pub2. Review. Review. Russian. doi: 10.1002/14651858.CD002955.pub4. Review. doi: 10.1016/j.clinthera.2014.06.010. Epub 2014 Jul 8. Review. doi: 10.1177/0003319712474335. Epub 2013 Jan 31. doi: 10.1016/j.bmcl.2012.03.093. Epub 2012 Apr 1. doi: 10.1002/dta.421. Epub 2012 Feb 28. doi: 10.1002/bjs.8895. Epub 2012 Oct 3. Review. Review. Br J Surg. 2013 Dec;100(13):1838. doi: 10.1002/bjs.9357. Br J Surg. 2013 Dec;100(13):1838-9. doi: 10.1002/bjs.9358. doi: 10.1136/bmj.b603. Review.
    15: Koller MF, Schmid M, Iten PX, Vonlanthen B, Bär W. Fatal intoxication with naftidrofuryl. Leg Med (Tokyo). 2009 Sep;11(5):229-33. doi: 10.1016/j.legalmed.2009.04.003. Epub 2009 Jun 10.
    17: Praxilene (naftidrofuryl). Drug Ther Bull. 1972 Nov 24;10(24):93-4. doi: 10.3310/hta15400. Review.

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
    摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知